Vertex Pharmaceuticals' new $200,000-a-year cystic fibrosis drug could help 90 percent of patients breathe. It's an amazing—and profitable—innovation. But will that windfall spur the 28-year-old startup to do it again?
David Zalik never graduated from high school, much less college. But the numbers whiz could do the math: Making money from both sides of a home-renovation loan, without the risk of defaults, can make you a billionaire
After resurrecting the French carmaker Groupe PSA, Carlos Tavares is taking on the global giants by gambling on bleeding-edge manufacturing techniques and selling services that support other companies' cars